We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New FDA-Cleared Assay to Aid in Diagnosis of Inflammatory Bowel Disease

By LabMedica International staff writers
Posted on 30 Jun 2014
Print article
A new quantitative ELISA for calprotectin helps diagnosis inflammatory bowel disease as well as differentiates it from irritable bowel syndrome.

INOVA Diagnostics Inc. (San Diego, CA, USA) has launched QUANTA Lite Calprotectin, an important new FDA-cleared in vitro diagnostic (IVD) assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and which can also help differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical findings.

The accurate detection of calprotectin levels in stool can provide critical information to physicians in determining appropriate care for patients suffering from gastrointestinal disorders. QUANTA Lite Calprotectin is a 96-well, quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin concentration in human feces.

This assay further expands the INOVA Diagnostics portfolio in the area of autoimmune gastrointestinal disorders. "We are very pleased to launch this high-performing assay to meet the increasing demand from laboratories worldwide," said Michael Mahler, PhD, Vice President of Research and Development for INOVA Diagnostics, "Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs. The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs." Roger Inglès, CEO of INOVA Diagnostics, added, "The benefits of fecal calprotectin testing are being recognized by healthcare systems around the world, as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK. As a worldwide leader in the autoimmunity IVD market, INOVA Diagnostics is perfectly positioned to quickly increase awareness and adoption of this important new test."

Related Links:

INOVA Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.